Abeomics goal is to provide well-validated antibodies for different applications to research community.
As per discussions in the recently concluded seminar on Antibody Validation: Standards, Policies, and Practices at Asilomar, September 25, 2016-September 27, 2016, we are in the process of converting all our monoclonal antibodies produced by hybridoma technology to recombinant monoclonal antibodies to obtain consistence results and prevent lot-to-lot variations. The specificities of the antibodies will be validated either by siRNA or CRISPER/Cas9 tools.
It has been a long time in the making....But we are delighted to finally reveal our newly redesigned website. With a bold new look and an enhanced navigation experience. We invite you to start exploring and we welcome your feedbacks.